{"created":"2023-06-19T09:40:24.464552+00:00","id":565,"links":{},"metadata":{"_buckets":{"deposit":"def20efc-50ba-422a-8912-5018ba7b56c4"},"_deposit":{"created_by":18,"id":"565","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"565"},"status":"published"},"_oai":{"id":"oai:yasuda-u.repo.nii.ac.jp:00000565","sets":["7:66"]},"author_link":["1224","1225"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-02-28","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"49","bibliographicPageEnd":"326","bibliographicPageStart":"317","bibliographic_titles":[{"bibliographic_title":"安田女子大学紀要","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of Yasuda Women's University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"　近年本邦でも分子標的薬であるソラフェニブやレンバチニブが乳頭癌や濾胞癌の局所進行・転移した切除不能の甲状腺分化癌に使用できることになった。それらの難治性甲状腺分化癌に対して分子標的薬は従来にない治療効果、延命効果が期待されている。\n　有害事象のgradeによっては減量あるいは休薬するとたちまち腫瘍の増悪をきたすことが示されていた。しかし、有害事象が生じるほど臨床効果も上がるという一面もあり、その副作用への対処を綿密に行うことは重要である。もちろん、分子標的薬の適応、開始時期（投与開始のタイミング）については慎重な判断が必要となる。患者の状態を適正に評価した上で治療によるベネフィットとリスクを考慮して、投与の適応・開始の時期を決めることが必要である。","subitem_description_type":"Abstract"}]},"item_10002_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24613/00000541","subitem_identifier_reg_type":"JaLC"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"安田女子大学","subitem_publisher_language":"ja"}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00242368","subitem_source_identifier_type":"NCID"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0289-6494","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮原, 裕","creatorNameLang":"ja"},{"creatorName":"ミヤハラ, ヒロシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hiroshi, Miyahara","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"02896494049032.pdf","filesize":[{"value":"904.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"02896494049032.pdf","url":"https://yasuda-u.repo.nii.ac.jp/record/565/files/02896494049032.pdf"},"version_id":"e9fdb688-3137-4729-9676-95b158f385e8"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"RAI不応","subitem_subject_scheme":"Other"},{"subitem_subject":"切除不能・再発甲状腺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的薬","subitem_subject_scheme":"Other"},{"subitem_subject":"ソラフェニブ","subitem_subject_scheme":"Other"},{"subitem_subject":"レンバチニブ","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"放射性ヨウ素内用療法抵抗性・切除不能甲状腺分化癌に対する分子標的治療薬　－とくに投与のタイミングについて－","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"放射性ヨウ素内用療法抵抗性・切除不能甲状腺分化癌に対する分子標的治療薬　－とくに投与のタイミングについて－","subitem_title_language":"ja"},{"subitem_title":"The Molecular Targeted Therapeutics for RAI-refractory Locally Advanced or Metastatic Intractable Differentiated Thyroid Cancer: Patient Selection and Timing of Administration","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"18","path":["66"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-03-20"},"publish_date":"2021-03-20","publish_status":"0","recid":"565","relation_version_is_last":true,"title":["放射性ヨウ素内用療法抵抗性・切除不能甲状腺分化癌に対する分子標的治療薬　－とくに投与のタイミングについて－"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-01-31T04:05:33.385052+00:00"}